Company intelligence / Profile preview
Theratome Bio
- Ownership
- Private
- Development stage
- Preclinical
Overview
Theratome Bio has developed a proprietary secretome-based therapeutic platform derived from adult stem cells. Its lead product, Thera‑101, is an injectable biologic targeting ischemic brain injury with first-in-human trials underway. The company’s technology also aims to double the shelf life of transplanted organs and address dry eye disease. Preclinical data support tissue-protective and regenerative effects across multiple indications.[1][4]
- Therapeutic areas
- PulmonologyNephrologyOphthalmologyOtherNeurology
- Modalities
- Cell-free biologics (secretome-based therapeutics derived from adult stem cells)[1][2][6]Regenerative medicine products (secretomes/exosomes/proteins/micro-RNAs/metabolites)[6]
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Theratome Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Theratome Bio.